Welcome to Autism Diagnostic Technologies, Inc.
We have developed a method of mapping the human brain using current technologies combined with a unique invention to compare normal brains to autistic, dyslexic, and Alzheimer’s affected brains.
Transforming the Diagnosis of Autism
- Diagnosis at any Age
- Results within minutes
- First Complete Autism Diagnosis System
The new technology reads an MRI scan to provide:
- Faster and more accurate analysis of the brain using three-dimensional mesh mapping to determine significant locations that correlate with abnormal brain structure and disease
- Diagnosis of Autism in infants as young as six months old at >94% rate of accuracy
- Measurement of the thickness of Cerebral White Matter (CWM) gyrification; and analysis of the shape and classification of brain segments based on this measurement
- The techonology is considered a smart technology, it can “learn” as more data is added, which will increase accuracy of diagnoses
The graphical user interface technology was developed with the help of physicians and is ready to be commercialized with this product. Autism Diagnostic Technologies, Inc. may in the future expand into already tested areas including Dyslexia, Alzheimer’s and Dementia.
Recent Health News – "Brain scans show early signs of autism in high-risk children".
Doctors in a national study,using the new technology, were able to predict with 80 percent accuracy which children would develop autism by age 2 through analysis of MRI brain scans at ages 6 months and 1 year — the earliest yet indicator of the possible development of the condition.
The first-of-its-kind research paves the way to predicting which children will develop the neurodevelopmental condition significantly before common behavioral symptoms emerge. Four and a half years is the standard age of diagnosis using conventional measures, which include a parental questionnaire.
Team members in the study, led by medical investigators at a major U.S. University and including 10 other institutions, credited their predictions’ accuracy to a customized algorithm that was applied to the data in classifying children most likely to meet criteria for autism by age 2. About 150 children were included in the research, and the subjects were limited to those considered at high risk of autism because of an older sibling’s diagnosis. The results were reported in the journal Nature.
The brain scans examined in the new analysis revealed enlargement in specific regions of the brain. The scans also revealed changes in brain volume, surface area and thickness of the organ at both 6 and 12 months of age. These features helped scientists predict the condition with unprecedented accuracy.
Breakthrough Technology Offers Early Diagnosis for Autism and Other Neurological Conditions
Using existing technology (MRI scan) the folds in a brain’s Cerebral White Matter are first mapped via gyrification. The resulting shapes are then analyzed by imaging technology. This new invention is comprised of machinery, systems, and software capable of producing a 3D map of a brain based on the scans. Using this 3D mesh map the brain’s neurological health can be evaluated. This provides the opportunity to diagnose and determine the severity of suspected neurological conditions.
Current Diagnostic Techniques for Autism
Diagnosing Autistic Spectrum Disorder (ASD) currently involves a number of specialized healthcare workers. Observation over long periods of time, as well as a series of tests are involved with determining if a child is on the Autism spectrum.. The costs and time associated with the diagnosis can be daunting. It is extremely difficult to diagnose a young child, which prevents early interventions.
New Technology Reveals the Autistic Brain as Young as 5-Month of Age
This new technology will diagnose a child as young as five months old, which will allow for early interventions and parents’ peace of mind. Providing accurate diagnostic imaging allows physicians the knowledge of which area of the brain is affected. With a 94%+ accuracy potential errors are minimized. The test reduces costs associated with specialized healthcare workers’ administering a battery of other tests for diagnosis.
Classifying a brain includes four steps:
- Segment the brain’s scanned image data associated with a specific cortex of the brain.
- Equalize and model segmented image data to generate a 3D mesh model of the brain.
- Map the 3D mesh model to a unit sphere.
- Compute the spherical harmonics for the delineation of the unit sphere.
On completion of the listed four steps, the spherical modules are used to classify the brain. This classification is based on the learned shape model developed from a collection of previous data of categorized brain images. The test can be repeated to follow the disease state over time.
Breakthrough Autism Diagnostic Technology Provides High Degree of Diagnostic Accuracy for Autism.
With an estimated 3.5 million Americans living with Autism Spectrum Disorder (ASD), the Center for Disease Control recommends all children be screened for developmental delays and disabilities at 18 and 24 month well baby visits. The recommendation specifically indicates the desirability of screening for ASD which, however, has been difficult if not impossible to conduct at such early age. It is anticipated that as many as 4 million Americans will suffer with ASD within the next 10 years. Currently, diagnosing ASD requires a team of specialists observing the individual over a period of time, which involves time and money.
As the only patented diagnostic system of its kind, this breakthrough technology provides healthcare workers and parents a 94%+ accuracy diagnosis of ASD as early as 5-months old. The technology can be integrated with any MRI scan equipment to perform automated diagnoses using scans from existing systems. Sold as software and turnkey system, the technology will perform the diagnostics.
The technology has proven equally accurate diagnosing dyslexia. Moreover, subject to confirmation through further research work, the technology can eventually be used to diagnose Alzheimer’s Disease with >90% accuracy. The high accuracy provides physicians, patients and caregivers a sense of security that a diagnosis is correct. With such degenerative disorders as Alzheimer’s Disease, the patient’s brain can be monitored with repeated scans. The technology can be expanded for use with other brain disorders and diseases.
The global ASD market was valued at $346.2 million in 2013 and $360.9 million in 2014. This market is expected to grow to $412.7 million by 2019, a compound annual growth rate (CAGR) of 2.7%. ASD is reported to occur in all racial, ethnic, and socioeconomic groups. ASD is about 4.5 times more common among boys (1 in 42) than among girls (1 in 189). Studies in Asia, Europe, and North America have identified individuals with ASD with an average prevalence of between 1% and 2%.
USE OF PROCEEDS
|Invested Sectors||If Maximum Offering Sold|
|Software Validation, FDA Data & Submission
|New Product Development
Our team of scientific experts and innovation commercialization entrepreneurs comes from a variety of fields and backgrounds, with a collective experience that range from founding startup biotech companies, to developing and marketing biopharmaceutical products, to designing clinical trials, and management of private and public companies.
Andrew Stewart Chief Executive Officer
Mr. Stewart combines over 40 years of experience in the Medical Device Industry. He has served as CEO of Autism Diagnosis Technology since May 2017. Previously, he held the position of CEO for Wipe-Rite Technologies, Inc. and Medeject, Inc. both medical device startups. Formerly from 2006 to 2013 he was CEO of EyeTect, LLC, a startup Medical Device company focused on Eye Tracking for diagnosing depth of consciousness monitoring. From 1994 through 2003, Mr. Stewart was the Vice President of Sales and Member of the Management Board for Ethicon, a Division of Johnson and Johnson, Inc. a Medical Device company focused upon Wound Closure. From 1986 to 1993 he was Vice President Sales and Marketing, Worldwide for Johnson and Johnson Professional, Inc., another J&J division focused on Neurosurgical and Cardiovascular Surgical Products. He served as Chairman and Vice Chairman of the Board of Directors for Somerset Medical Center from 1994 to 2003. He graduated from Kenyon College with double majors in Economics and Political Science in 1970. He graduated from Harvard Business School with an AMP in General Management in 1993. He is an Elder of the Presbyterian Church.
Joerg H. KlaubeChief Financial Officer
Mr. Klaube‘s career encompasses a broad range of appointments in corporate financial management, controllership and administrative functions, in a variety of business environments including publicly held companies. He joined the Company in 2018. From 2013 to 2017 he held the position of chief financial officer at Turnpoint Medical Devices Inc., a designer and marketer of specialized infusion pumps. Prior to that he served as chief financial officer for the telecommunications holding company E. Oliver Capital Group and the software design and computer marketing firms Magnitude Information Systems Inc. and Unitronix Corporation. Before that, he was employed for sixteen years with the U.S. subsidiary of Siemens AG, where lastly he served as Director of Business Administration in the Telecommunications Division. He graduated from the Banking School in Berlin, Germany, and holds a Master Degree in Business Administration from Rutgers University.
Mr. Ali combines over 19 years of experience in the pharmacy industry and as an entrepreneur involving work in Retail and Hospital. Advised a fortune 100 company regarding logistics and international marketing. Advised another fortune 100 company regarding new technology. Managing member of Highlands Harris LLC. Partner at Academic Technology Ventures since 2015. Cofounder, Autism Diagnostic technology since 2015.
Mr. Pottinger combines over 4 years of experience in technology commercialization senior management following a 9 year career as a real estate investor and professional athlete. Previously, he has been involved in Plasma Stream Technologies and Predictive Aviation Analytics holding positions including Chief Executive Officer and board member. From 2009 through 2015, Mr. Pottinger was the President and CEO for Ark Management, Inc., a real estate and property management company. From 20014 to present, he has been CEO of Academic Technology Ventures, Inc., a company involved in technology commercialization. Mr. Pottinger is also currently a director of Thermo-Flex Technologies, Inc., a company developing cooling systems for large corporations in various industry segments including the mattress and apparel industries. He has an undergraduate degree from McMaster University and an MBA from The Schulich School of Business at York University in Toronto, Canada.
Mackenzie Kim Development
Mackenzie joined Autism Diagnostic in 2018 from Mitsubishi UFJ Financial Group (MUFG), where he structured financial derivative products for the investment banks’ clients and worked on developing strategic initiatives across film, entertainment, technology, and real estate. Prior to MUFG, Mackenzie worked as an Analyst at Harvey & Company, an M&A advisory firm in Newport Beach, California where he evaluated new investment opportunities and supported existing portfolio companies within the distribution and manufacturing space.
Mackenzie has always had a passion for start-ups and technology innovation, founding his own mobile app and serving as an advisor for a successful Los Angeles based internet marketing start-up. He has also been a guest speaker including most recently presenting a TEDx Talk on the importance of face-to-face communication in a world of technology and social media. After playing soccer semi-professionally for Toronto FC’s Academy team, Mackenzie graduated with honors from Loyola Marymount University in Los Angeles, where he earned his BBA in Finance with a focus in Entrepreneurship.
John PaulsonPhD, Advisor
25 years Johnson & Johnson where he held the position of Vice President of Regulatory and Clinical Affairs. Conducted all regulatory and QA due diligence for large medical devices company within J&J, resulting in several large acquisition, divestitures and equity divestments. Led multi-company development of product life cycle management system for several J&J device firms.
Manuel CasanovaMD, Advisor
Chairman Neuro Therapeutics, USC, Inventor. Dr. Casanova belonged to the founding board of the National Alliance for Autism Research (now Autism Speaks) and the Autism Tissue Board. He has served on the Board of Directors or Scientific Advisory Board of numerous organizations (e.g., Autism Research Institute, Generation Rescue, On Mental Health, Families for Effective Autism Treatment, Clearly Present Foundation) and is presently on the editorial board of 15 different medical journals
Ayman El-BazPh.D, Advisor
Dr. El-Baz has twelve years of hands-on experience in the fields of bio imaging modeling and computer-assisted diagnostic systems. He has developed new techniques for analyzing 3D medical images. His work has been reported at several prestigious international conferences (e.g., CVPR, ICCV, MICCAI, etc.) and in journals (e.g., IEEE TIP, IEEE TBME, IEEE TITB, Brain, etc.). His work related to novel image analysis techniques for lung cancer and autism diagnosis have earned him multiple awards, including: first place at the annual Research Louisville 2002, 2005, 2006, 2007, 2008, 2010, 2011 and 2012 meetings, and the “Best Paper Award in Medical Image Processing” from the prestigious ICGST International Conference on Graphics, Vision and Image Processing (GVIP-2005). Dr. El-Baz has authored or coauthored more than 300 technical articles. On February 1, 2016, Dr. El-Baz became the acting chair of Bioengineering of the University of Louisville.